{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T01:53:53Z","timestamp":1784166833266,"version":"3.55.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T00:00:00Z","timestamp":1523664000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11914-018-0439-7","type":"journal-article","created":{"date-parts":[[2018,4,14]],"date-time":"2018-04-14T00:15:09Z","timestamp":1523664909000},"page":"256-268","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Human Genetics of Sclerosing Bone Disorders"],"prefix":"10.1007","volume":"16","author":[{"given":"Rapha\u00ebl","family":"De Ridder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eveline","family":"Boudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Van Hul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,14]]},"reference":[{"issue":"8","key":"439_CR1","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S0301-472X(99)00061-2","volume":"27","author":"GD Roodman","year":"1999","unstructured":"Roodman GD. Cell biology of the osteoclast. Exp Hematol. 1999;27(8):1229\u201341.","journal-title":"Exp Hematol"},{"issue":"1\u20132","key":"439_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11154-006-9009-x","volume":"7","author":"A Bruzzaniti","year":"2006","unstructured":"Bruzzaniti A, Baron R. Molecular regulation of osteoclast activity. Rev Endocr Metab Disord. 2006;7(1\u20132):123\u201339. \n                      https:\/\/doi.org\/10.1007\/s11154-006-9009-x\n                      \n                    .","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"439_CR3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00223-005-0027-6","volume":"77","author":"W Balemans","year":"2005","unstructured":"Balemans W, Van Wesenbeeck L, Van Hul W. A clinical and molecular overview of the human osteopetroses. Calcif Tissue Int. 2005;77(5):263\u201374. \n                      https:\/\/doi.org\/10.1007\/s00223-005-0027-6\n                      \n                    .","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"439_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.berh.2007.12.011","volume":"22","author":"MC Vernejoul de","year":"2008","unstructured":"de Vernejoul MC. Sclerosing bone disorders. Best Pract Res Clin Rheumatol. 2008;22(1):71\u201383. \n                      https:\/\/doi.org\/10.1016\/j.berh.2007.12.011\n                      \n                    .","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"439_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bone.2007.08.029","volume":"42","author":"A Fattore Del","year":"2008","unstructured":"Del Fattore A, Cappariello A, Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone. 2008;42(1):19\u201329. \n                      https:\/\/doi.org\/10.1016\/j.bone.2007.08.029\n                      \n                    .","journal-title":"Bone"},{"issue":"4","key":"439_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1136\/jmedgenet-2011-100520.","volume":"49","author":"M Aker","year":"2012","unstructured":"Aker M, Rouvinski A, Hashavia S, Ta-Shma A, Shaag A, Zenvirt S, et al. An SNX10 mutation causes malignant osteopetrosis of infancy. J Med Genet. 2012;49(4):221\u20136. \n                      https:\/\/doi.org\/10.1136\/jmedgenet-2011-100520.","journal-title":"J Med Genet"},{"issue":"4","key":"439_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nm842","volume":"9","author":"N Chalhoub","year":"2003","unstructured":"Chalhoub N, Benachenhou N, Rajapurohitam V, Pata M, Ferron M, Frattini A, et al. Grey-lethal mutation induces severe malignant autosomal recessive osteopetrosis in mouse and human. Nat Med. 2003;9(4):399\u2013406. \n                      https:\/\/doi.org\/10.1038\/nm842\n                      \n                    .","journal-title":"Nat Med"},{"issue":"25","key":"439_CR8","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1093\/hmg\/10.25.2861","volume":"10","author":"E Cleiren","year":"2001","unstructured":"Cleiren E, Benichou O, Van Hul E, Gram J, Bollerslev J, Singer FR, et al. Albers-Schonberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet. 2001;10(25):2861\u20137.","journal-title":"Hum Mol Genet"},{"issue":"1","key":"439_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ajhg.2008.06.015","volume":"83","author":"MM Guerrini","year":"2008","unstructured":"Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazio A, et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet. 2008;83(1):64\u201376. \n                      https:\/\/doi.org\/10.1016\/j.ajhg.2008.06.015\n                      \n                    .","journal-title":"Am J Hum Genet"},{"issue":"2","key":"439_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0092-8674(01)00206-9","volume":"104","author":"U Kornak","year":"2001","unstructured":"Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, et al. Loss of the ClC-7 chloride channel leads to osteopetrosis in mice and man. Cell. 2001;104(2):205\u201315.","journal-title":"Cell"},{"issue":"13","key":"439_CR11","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/hmg\/9.13.2059","volume":"9","author":"U Kornak","year":"2000","unstructured":"Kornak U, Schulz A, Friedrich W, Uhlhaas S, Kremens B, Voit T, et al. Mutations in the a3 subunit of the vacuolar H(+)-ATPase cause infantile malignant osteopetrosis. Hum Mol Genet. 2000;9(13):2059\u201363.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"439_CR12","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/jbmr.1849","volume":"28","author":"A Pangrazio","year":"2013","unstructured":"Pangrazio A, Fasth A, Sbardellati A, Orchard PJ, Kasow KA, Raza J, et al. SNX10 mutations define a subgroup of human autosomal recessive osteopetrosis with variable clinical severity. J Bone Miner Res. 2013;28(5):1041\u20139. \n                      https:\/\/doi.org\/10.1002\/jbmr.1849\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"7","key":"439_CR13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1359\/jbmr.060403","volume":"21","author":"A Pangrazio","year":"2006","unstructured":"Pangrazio A, Poliani PL, Megarbane A, Lefranc G, Lanino E, Di Rocco M, et al. Mutations in OSTM1 (grey lethal) define a particularly severe form of autosomal recessive osteopetrosis with neural involvement. J Bone Miner Res. 2006;21(7):1098\u2013105. \n                      https:\/\/doi.org\/10.1359\/jbmr.060403\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"3","key":"439_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1056\/NEJM198507183130302","volume":"313","author":"WS Sly","year":"1985","unstructured":"Sly WS, Whyte MP, Sundaram V, Tashian RE, Hewett-Emmett D, Guibaud P, et al. Carbonic anhydrase II deficiency in 12 families with the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. N Engl J Med. 1985;313(3):139\u201345. \n                      https:\/\/doi.org\/10.1056\/NEJM198507183130302\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"20","key":"439_CR15","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1093\/hmg\/11.20.2371","volume":"11","author":"A Smahi","year":"2002","unstructured":"Smahi A, Courtois G, Rabia SH, Doffinger R, Bodemer C, Munnich A, et al. The NF-kappaB signalling pathway in human diseases: from incontinentia pigmenti to ectodermal dysplasias and immune-deficiency syndromes. Hum Mol Genet. 2002;11(20):2371\u20135.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"439_CR16","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1359\/jbmr.2003.18.10.1740","volume":"18","author":"A Frattini","year":"2003","unstructured":"Frattini A, Pangrazio A, Susani L, Sobacchi C, Mirolo M, Abinun M, et al. Chloride channel ClCN7 mutations are responsible for severe recessive, dominant, and intermediate osteopetrosis. J Bone Miner Res. 2003;18(10):1740\u20137. \n                      https:\/\/doi.org\/10.1359\/jbmr.2003.18.10.1740\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"6","key":"439_CR17","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1359\/jbmr.2002.17.6.1111","volume":"17","author":"E Hul Van","year":"2002","unstructured":"Van Hul E, Gram J, Bollerslev J, Van Wesenbeeck L, Mathysen D, Andersen PE, et al. Localization of the gene causing autosomal dominant osteopetrosis type I to chromosome 11q12-13. J Bone Miner Res. 2002;17(6):1111\u20137. \n                      https:\/\/doi.org\/10.1359\/jbmr.2002.17.6.1111\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"8","key":"439_CR18","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1359\/jbmr.2003.18.8.1513","volume":"18","author":"SG Waguespack","year":"2003","unstructured":"Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, et al. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II. J Bone Miner Res. 2003;18(8):1513\u20138. \n                      https:\/\/doi.org\/10.1359\/jbmr.2003.18.8.1513\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"4","key":"439_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1172\/JCI30328.","volume":"117","author":"L Wesenbeeck Van","year":"2007","unstructured":"Van Wesenbeeck L, Odgren PR, Coxon FP, Frattini A, Moens P, Perdu B, et al. Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans. J Clin Invest. 2007;117(4):919\u201330. \n                      https:\/\/doi.org\/10.1172\/JCI30328.","journal-title":"J Clin Invest"},{"issue":"1","key":"439_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11914-018-0415-2","volume":"16","author":"E Palagano","year":"2018","unstructured":"Palagano E, Menale C, Sobacchi C, Villa A. Genetics of osteopetrosis. Curr Osteoporos Rep. 2018;16(1):13\u201325. \n                      https:\/\/doi.org\/10.1007\/s11914-018-0415-2\n                      \n                    .","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"439_CR21","first-page":"172","volume":"5","author":"SC Marks Jr","year":"1987","unstructured":"Marks SC Jr. Osteopetrosis\u2014multiple pathways for the interception of osteoclast function. Appl Pathol. 1987;5(3):172\u201383.","journal-title":"Appl Pathol"},{"key":"439_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.bone.2017.02.002","volume":"102","author":"A Teti","year":"2017","unstructured":"Teti A, Econs MJ. Osteopetroses, emphasizing potential approaches to treatment. Bone. 2017;102:50\u20139. \n                      https:\/\/doi.org\/10.1016\/j.bone.2017.02.002\n                      \n                    .","journal-title":"Bone"},{"issue":"12","key":"439_CR23","first-page":"78","volume":"10","author":"Y Sugiura","year":"1974","unstructured":"Sugiura Y, Yamada Y, Ko J. Pycnodysostosis in Japan: report of six cases and a review of Japaneses literature. Birth Defects Orig Artic Ser. 1974;10(12):78\u201398.","journal-title":"Birth Defects Orig Artic Ser"},{"key":"439_CR24","first-page":"999","volume":"70","author":"P Maroteaux","year":"1962","unstructured":"Maroteaux P, Lamy M. Pyknodysostosis. Presse Med. 1962;70:999\u20131002.","journal-title":"Presse Med"},{"issue":"5","key":"439_CR25","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/humu.9490","volume":"28","author":"M Donnarumma","year":"2007","unstructured":"Donnarumma M, Regis S, Tappino B, Rosano C, Assereto S, Corsolini F, et al. Molecular analysis and characterization of nine novel CTSK mutations in twelve patients affected by pycnodysostosis. Mutation in brief #961. Online. Hum Mutat. 2007;28(5):524. \n                      https:\/\/doi.org\/10.1002\/humu.9490\n                      \n                    .","journal-title":"Hum Mutat"},{"issue":"5279","key":"439_CR26","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","volume":"273","author":"BD Gelb","year":"1996","unstructured":"Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science. 1996;273(5279):1236\u20138.","journal-title":"Science"},{"issue":"4","key":"439_CR27","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1074\/jbc.271.4.2126","volume":"271","author":"D Bromme","year":"1996","unstructured":"Bromme D, Okamoto K, Wang BB, Biroc S. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem. 1996;271(4):2126\u201332.","journal-title":"J Biol Chem"},{"issue":"1","key":"439_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1006\/bbrc.1995.1013","volume":"206","author":"T Inaoka","year":"1995","unstructured":"Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem Biophys Res Commun. 1995;206(1):89\u201396. \n                      https:\/\/doi.org\/10.1006\/bbrc.1995.1013\n                      \n                    .","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"439_CR29","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/jbmr.5650100809.","volume":"10","author":"YP Li","year":"1995","unstructured":"Li YP, Alexander M, Wucherpfennig AL, Yelick P, Chen W, Stashenko P. Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas. J Bone Miner Res. 1995;10(8):1197\u2013202. \n                      https:\/\/doi.org\/10.1002\/jbmr.5650100809.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"439_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0014-5793(94)01349-6","volume":"357","author":"GP Shi","year":"1995","unstructured":"Shi GP, Chapman HA, Bhairi SM, DeLeeuw C, Reddy VY, Weiss SJ. Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett. 1995;357(2):129\u201334.","journal-title":"FEBS Lett"},{"issue":"1","key":"439_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/BF02557674","volume":"37","author":"V Everts","year":"1985","unstructured":"Everts V, Aronson DC, Beertsen W. Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis. Calcif Tissue Int. 1985;37(1):25\u201331.","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"439_CR32","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1007\/BF02012448","volume":"23","author":"G Nishimura","year":"1993","unstructured":"Nishimura G, Kozlowski K. Osteosclerotic metaphyseal dysplasia. Pediatr Radiol. 1993;23(6):450\u20132.","journal-title":"Pediatr Radiol"},{"key":"439_CR33","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1136\/jmedgenet-2016-103756","volume":"53","author":"A Iida","year":"2016","unstructured":"\u2022 Iida A, Xing W, Docx MK, Nakashima T, Wang Z, Kimizuka M, et al. Identification of biallelic LRRK1 mutations in osteosclerotic metaphyseal dysplasia and evidence for locus heterogeneity. J Med Genet. 2016;53:568\u201374. \n                      https:\/\/doi.org\/10.1136\/jmedgenet-2016-103756\n                      \n                    . Using WES, the authors identified the disease-causing gene for OSMD and deliver functional evidence.","journal-title":"J Med Genet"},{"key":"439_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","volume":"96","author":"AH Lierop van","year":"2017","unstructured":"van Lierop AH, Appelman-Dijkstra NM, Papapoulos SE. Sclerostin deficiency in humans. Bone. 2017;96:51\u201362. \n                      https:\/\/doi.org\/10.1016\/j.bone.2016.10.010\n                      \n                    .","journal-title":"Bone"},{"issue":"4","key":"439_CR35","first-page":"355","volume":"6","author":"W Balemans","year":"2006","unstructured":"Balemans W, Van Hul W. Human genetics of SOST. J Musculoskelet Neuronal Interact. 2006;6(4):355\u20136.","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"2","key":"439_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1136\/jmg.39.2.91","volume":"39","author":"W Balemans","year":"2002","unstructured":"Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet. 2002;39(2):91\u20137.","journal-title":"J Med Genet"},{"issue":"35","key":"439_CR37","doi-asserted-by":"publisher","first-page":"14092","DOI":"10.1073\/pnas.1207188109","volume":"109","author":"NM Collette","year":"2012","unstructured":"Collette NM, Genetos DC, Economides AN, Xie L, Shahnazari M, Yao W, et al. Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc Natl Acad Sci U S A. 2012;109(35):14092\u20137. \n                      https:\/\/doi.org\/10.1073\/pnas.1207188109\n                      \n                    .","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"439_CR38","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/jbmr.1794","volume":"28","author":"AH Lierop van","year":"2013","unstructured":"van Lierop AH, Hamdy NA, van Egmond ME, Bakker E, Dikkers FG, Papapoulos SE. Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers. J Bone Miner Res. 2013;28(4):848\u201354. \n                      https:\/\/doi.org\/10.1002\/jbmr.1794\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"5","key":"439_CR39","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","volume":"10","author":"W Balemans","year":"2001","unstructured":"Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537\u201343.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"439_CR40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/318811","volume":"68","author":"ME Brunkow","year":"2001","unstructured":"Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577\u201389.","journal-title":"Am J Hum Genet"},{"issue":"12","key":"439_CR41","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/jbmr.474","volume":"26","author":"AH Lierop van","year":"2011","unstructured":"van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res. 2011;26(12):2804\u201311. \n                      https:\/\/doi.org\/10.1002\/jbmr.474\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"4","key":"439_CR42","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1002\/jbmr.2782","volume":"31","author":"I Fijalkowski","year":"2016","unstructured":"\u2022 Fijalkowski I, Geets E, Steenackers E, Van Hoof V, Ramos FJ, Mortier G, et al. A novel domain-specific mutation in a sclerosteosis patient suggests a role of LRP4 as an anchor for sclerostin in human bone. J Bone Miner Res. 2016;31(4):874\u201381. \n                      https:\/\/doi.org\/10.1002\/jbmr.2782\n                      \n                    . In this study, the authors delivered evidence for the functional implications of mutations in the cavity of the third b-propeller domain in the pathogenesis of sclerosteosis.","journal-title":"J Bone Miner Res"},{"issue":"22","key":"439_CR43","doi-asserted-by":"publisher","first-page":"19489","DOI":"10.1074\/jbc.M110.190330","volume":"286","author":"O Leupin","year":"2011","unstructured":"Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem. 2011;286(22):19489\u2013500. \n                      https:\/\/doi.org\/10.1074\/jbc.M110.190330\n                      \n                    .","journal-title":"J Biol Chem"},{"issue":"20","key":"439_CR44","doi-asserted-by":"publisher","first-page":"19883","DOI":"10.1074\/jbc.M413274200","volume":"280","author":"X Li","year":"2005","unstructured":"Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling. J Biol Chem. 2005;280(20):19883\u20137. \n                      https:\/\/doi.org\/10.1074\/jbc.M413274200\n                      \n                    .","journal-title":"J Biol Chem"},{"issue":"8","key":"439_CR45","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/jbmr.3160","volume":"32","author":"E Boudin","year":"2017","unstructured":"Boudin E, Yorgan TA, Fijalkowski I, Sonntag S, Steenackers E, Hendrickx G, et al. The Lrp4 R1170Q homozygous knock-in mouse recapitulates the bone phenotype of sclerosteosis in humans. J Bone Miner Res. 2017;32(8):1739\u201349. \n                      https:\/\/doi.org\/10.1002\/jbmr.3160\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"6","key":"439_CR46","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1210\/en.2006-1352","volume":"148","author":"W Balemans","year":"2007","unstructured":"Balemans W, Van Hul W. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes. Endocrinology. 2007;148(6):2622\u20139. \n                      https:\/\/doi.org\/10.1210\/en.2006-1352\n                      \n                    .","journal-title":"Endocrinology"},{"issue":"20","key":"439_CR47","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa013444","volume":"346","author":"LM Boyden","year":"2002","unstructured":"Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513\u201321. \n                      https:\/\/doi.org\/10.1056\/NEJMoa013444\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"1","key":"439_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1086\/338450","volume":"70","author":"RD Little","year":"2002","unstructured":"Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, et al. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002;70(1):11\u20139. \n                      https:\/\/doi.org\/10.1086\/338450\n                      \n                    .","journal-title":"Am J Hum Genet"},{"issue":"3","key":"439_CR49","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1086\/368277","volume":"72","author":"L Wesenbeeck Van","year":"2003","unstructured":"Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Benichou O, Scopelliti D, et al. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet. 2003;72(3):763\u201371. \n                      https:\/\/doi.org\/10.1086\/368277\n                      \n                    .","journal-title":"Am J Hum Genet"},{"issue":"2","key":"439_CR50","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.semarthrit.2013.01.004","volume":"43","author":"E Boudin","year":"2013","unstructured":"Boudin E, Fijalkowski I, Piters E, Van Hul W. The role of extracellular modulators of canonical Wnt signaling in bone metabolism and diseases. Semin Arthritis Rheum. 2013;43(2):220\u201340. \n                      https:\/\/doi.org\/10.1016\/j.semarthrit.2013.01.004\n                      \n                    .","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"439_CR51","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1359\/jbmr.070211","volume":"22","author":"W Balemans","year":"2007","unstructured":"Balemans W, Devogelaer JP, Cleiren E, Piters E, Caussin E, Van Hul W. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling. J Bone Miner Res. 2007;22(5):708\u201316. \n                      https:\/\/doi.org\/10.1359\/jbmr.070211\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"6","key":"439_CR52","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00223-008-9130-9","volume":"82","author":"W Balemans","year":"2008","unstructured":"Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L, Warman ML, et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Calcif Tissue Int. 2008;82(6):445\u201353. \n                      https:\/\/doi.org\/10.1007\/s00223-008-9130-9\n                      \n                    .","journal-title":"Calcif Tissue Int"},{"issue":"11","key":"439_CR53","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1359\/jbmr.060810","volume":"21","author":"DL Ellies","year":"2006","unstructured":"Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, et al. Bone density ligand, sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res. 2006;21(11):1738\u201349. \n                      https:\/\/doi.org\/10.1359\/jbmr.060810\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"5","key":"439_CR54","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","volume":"8","author":"DA Glass 2nd","year":"2005","unstructured":"Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8(5):751\u201364. \n                      https:\/\/doi.org\/10.1016\/j.devcel.2005.02.017\n                      \n                    .","journal-title":"Dev Cell"},{"issue":"5","key":"439_CR55","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00439-011-0947-3","volume":"129","author":"SJ Kim","year":"2011","unstructured":"Kim SJ, Bieganski T, Sohn YB, Kozlowski K, Semenov M, Okamoto N, et al. Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. Hum Genet. 2011;129(5):497\u2013502. \n                      https:\/\/doi.org\/10.1007\/s00439-011-0947-3\n                      \n                    .","journal-title":"Hum Genet"},{"issue":"20","key":"439_CR56","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/ajmg.a.31938","volume":"143A","author":"T Bieganski","year":"2007","unstructured":"Bieganski T, Baranska D, Miastkowska I, Kobielski A, Gorska-Chrzastek M, Kozlowski K. A boy with severe craniodiaphyseal dysplasia and apparently normal mother. Am J Med Genet A. 2007;143A(20):2435\u201343. \n                      https:\/\/doi.org\/10.1002\/ajmg.a.31938\n                      \n                    .","journal-title":"Am J Med Genet A"},{"issue":"1","key":"439_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1302\/0301-620X.35B1.89","volume":"35-B","author":"RL Hurt","year":"1953","unstructured":"Hurt RL. Osteopathia striata-Voorhoeve\u2019s disease: report of a case presenting the features of osteopathia striata and osteopetrosis. J Bone Joint Surg Br. 1953;35-B(1):89\u201396.","journal-title":"J Bone Joint Surg Br"},{"issue":"1","key":"439_CR58","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ajmg.a.30107","volume":"129A","author":"LM Ward","year":"2004","unstructured":"Ward LM, Rauch F, Travers R, Roy M, Montes J, Chabot G, et al. Osteopathia striata with cranial sclerosis: clinical, radiological, and bone histological findings in an adolescent girl. Am J Med Genet A. 2004;129A(1):8\u201312. \n                      https:\/\/doi.org\/10.1002\/ajmg.a.30107\n                      \n                    .","journal-title":"Am J Med Genet A"},{"issue":"1","key":"439_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/ng.270","volume":"41","author":"ZA Jenkins","year":"2009","unstructured":"Jenkins ZA, van Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R, Pearl E, et al. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet. 2009;41(1):95\u2013100. \n                      https:\/\/doi.org\/10.1038\/ng.270\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"1","key":"439_CR60","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1359\/jbmr.090707","volume":"25","author":"B Perdu","year":"2010","unstructured":"Perdu B, de Freitas F, Frints SG, Schouten M, Schrander-Stumpel C, Barbosa M, et al. Osteopathia striata with cranial sclerosis owing to WTX gene defect. J Bone Miner Res. 2010;25(1):82\u201390. \n                      https:\/\/doi.org\/10.1359\/jbmr.090707\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"4","key":"439_CR61","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1399-0004.2010.01553.x","volume":"80","author":"B Perdu","year":"2011","unstructured":"Perdu B, Lakeman P, Mortier G, Koenig R, Lachmeijer AM, Van Hul W. Two novel WTX mutations underscore the unpredictability of male survival in osteopathia striata with cranial sclerosis. Clin Genet. 2011;80(4):383\u20138. \n                      https:\/\/doi.org\/10.1111\/j.1399-0004.2010.01553.x\n                      \n                    .","journal-title":"Clin Genet"},{"issue":"22","key":"439_CR62","doi-asserted-by":"publisher","first-page":"19204","DOI":"10.1074\/jbc.M111.224881","volume":"286","author":"K Tanneberger","year":"2011","unstructured":"Tanneberger K, Pfister AS, Kriz V, Bryja V, Schambony A, Behrens J. Structural and functional characterization of the Wnt inhibitor APC membrane recruitment 1 (Amer1). J Biol Chem. 2011;286(22):19204\u201314. \n                      https:\/\/doi.org\/10.1074\/jbc.M111.224881\n                      \n                    .","journal-title":"J Biol Chem"},{"issue":"5827","key":"439_CR63","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1126\/science\/1141515","volume":"316","author":"MB Major","year":"2007","unstructured":"Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, et al. Wilms tumor suppressor WTX negatively regulates WNT\/beta-catenin signaling. Science. 2007;316(5827):1043\u20136. \n                      https:\/\/doi.org\/10.1126\/science\/1141515\n                      \n                    .","journal-title":"Science"},{"issue":"2","key":"439_CR64","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jobcr.2017.04.007","volume":"7","author":"K Martin","year":"2017","unstructured":"Martin K, Nathwani S, Bunyan R. Craniometaphyseal dysplasia: a review and novel oral manifestation. J Oral Biol Craniofac Res. 2017;7(2):134\u20136. \n                      https:\/\/doi.org\/10.1016\/j.jobcr.2017.04.007\n                      \n                    .","journal-title":"J Oral Biol Craniofac Res"},{"key":"439_CR65","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1159\/000381048","volume":"28","author":"MZ Mughal","year":"2015","unstructured":"Mughal MZ, Padidela R. Miscellaneous bone disorders. Endocr Dev. 2015;28:226\u201346. \n                      https:\/\/doi.org\/10.1159\/000381048\n                      \n                    .","journal-title":"Endocr Dev"},{"issue":"6","key":"439_CR66","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1086\/320612","volume":"68","author":"E Reichenberger","year":"2001","unstructured":"Reichenberger E, Tiziani V, Watanabe S, Park L, Ueki Y, Santanna C, et al. Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK. Am J Hum Genet. 2001;68(6):1321\u20136. \n                      https:\/\/doi.org\/10.1086\/320612\n                      \n                    .","journal-title":"Am J Hum Genet"},{"issue":"8","key":"439_CR67","doi-asserted-by":"publisher","first-page":"e73576","DOI":"10.1371\/journal.pone.0073576","volume":"8","author":"Y Hu","year":"2013","unstructured":"Hu Y, Chen IP, de Almeida S, Tiziani V, Do Amaral CM, Gowrishankar K, et al. A novel autosomal recessive GJA1 missense mutation linked to craniometaphyseal dysplasia. PLoS One. 2013;8(8):e73576. \n                      https:\/\/doi.org\/10.1371\/journal.pone.0073576\n                      \n                    .","journal-title":"PLoS One"},{"issue":"6","key":"439_CR68","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1086\/509881","volume":"79","author":"KA Gurley","year":"2006","unstructured":"Gurley KA, Reimer RJ, Kingsley DM. Biochemical and genetic analysis of ANK in arthritis and bone disease. Am J Hum Genet. 2006;79(6):1017\u201329. \n                      https:\/\/doi.org\/10.1086\/509881\n                      \n                    .","journal-title":"Am J Hum Genet"},{"issue":"5","key":"439_CR69","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.stemcr.2017.09.016","volume":"9","author":"IP Chen","year":"2017","unstructured":"\u2022 Chen IP, Luxmi R, Kanaujiya J, Hao Z, Reichenberger EJ. Craniometaphyseal dysplasia mutations in ANKH negatively affect human induced pluripotent stem cell differentiation into osteoclasts. Stem Cell Rep. 2017;9(5):1369\u201376. \n                      https:\/\/doi.org\/10.1016\/j.stemcr.2017.09.016\n                      \n                    . This study explores the use of hiPSCs in in vitro functional analyses of osteoclast biology and offers a new tool for investigating molecular mechanisms in diseases as demonstrated by the results on ANKH mutations to study craniometaphyseal dysplasia.","journal-title":"Stem Cell Rep"},{"issue":"5","key":"439_CR70","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/hmg\/ddq541","volume":"20","author":"IP Chen","year":"2011","unstructured":"Chen IP, Wang L, Jiang X, Aguila HL, Reichenberger EJ. A Phe377del mutation in ANK leads to impaired osteoblastogenesis and osteoclastogenesis in a mouse model for craniometaphyseal dysplasia (CMD). Hum Mol Genet. 2011;20(5):948\u201361. \n                      https:\/\/doi.org\/10.1093\/hmg\/ddq541\n                      \n                    .","journal-title":"Hum Mol Genet"},{"key":"439_CR71","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.semcdb.2015.12.017","volume":"50","author":"JP Stains","year":"2016","unstructured":"Stains JP, Civitelli R. Connexins in the skeleton. Semin Cell Dev Biol. 2016;50:31\u20139. \n                      https:\/\/doi.org\/10.1016\/j.semcdb.2015.12.017\n                      \n                    .","journal-title":"Semin Cell Dev Biol"},{"issue":"3","key":"439_CR72","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1161\/01.RES.82.3.360","volume":"82","author":"J Ya","year":"1998","unstructured":"Ya J, Erdtsieck-Ernste EB, de Boer PA, van Kempen MJ, Jongsma H, Gros D, et al. Heart defects in connexin43-deficient mice. Circ Res. 1998;82(3):360\u20136.","journal-title":"Circ Res"},{"issue":"5205","key":"439_CR73","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1126\/science.7892609","volume":"267","author":"AG Reaume","year":"1995","unstructured":"Reaume AG, de Sousa PA, Kulkarni S, Langille BL, Zhu D, Davies TC, et al. Cardiac malformation in neonatal mice lacking connexin43. Science. 1995;267(5205):1831\u20134.","journal-title":"Science"},{"issue":"4","key":"439_CR74","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1083\/jcb.151.4.931","volume":"151","author":"F Lecanda","year":"2000","unstructured":"Lecanda F, Warlow PM, Sheikh S, Furlan F, Steinberg TH, Civitelli R. Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J Cell Biol. 2000;151(4):931\u201344.","journal-title":"J Cell Biol"},{"issue":"Pt 20","key":"439_CR75","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1242\/jcs.03162.","volume":"119","author":"DJ Chung","year":"2006","unstructured":"Chung DJ, Castro CH, Watkins M, Stains JP, Chung MY, Szejnfeld VL, et al. Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J Cell Sci. 2006;119(Pt 20):4187\u201398. \n                      https:\/\/doi.org\/10.1242\/jcs.03162.","journal-title":"J Cell Sci"},{"issue":"8","key":"439_CR76","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1091\/mbc.E10-07-0571","volume":"22","author":"M Watkins","year":"2011","unstructured":"Watkins M, Grimston SK, Norris JY, Guillotin B, Shaw A, Beniash E, et al. Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. Mol Biol Cell. 2011;22(8):1240\u201351. \n                      https:\/\/doi.org\/10.1091\/mbc.E10-07-0571\n                      \n                    .","journal-title":"Mol Biol Cell"},{"issue":"3","key":"439_CR77","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1242\/jcs.197285","volume":"130","author":"MC Moorer","year":"2017","unstructured":"\u2022 Moorer MC, Hebert C, Tomlinson RE, Iyer SR, Chason M, Stains JP. Defective signaling, osteoblastogenesis and bone remodeling in a mouse model of connexin 43 C-terminal truncation. J Cell Sci. 2017;130(3):531\u201340. \n                      https:\/\/doi.org\/10.1242\/jcs.197285\n                      \n                    . The results reported in this work expand on the knowledge on connexin 43 in the regulation of cell function and bone acquisition using a truncated connexin 43 mouse model.","journal-title":"J Cell Sci"},{"issue":"1","key":"439_CR78","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11914-017-0345-4","volume":"15","author":"MC Moorer","year":"2017","unstructured":"Moorer MC, Stains JP. Connexin43 and the intercellular signaling network regulating skeletal remodeling. Curr Osteoporos Rep. 2017;15(1):24\u201331. \n                      https:\/\/doi.org\/10.1007\/s11914-017-0345-4\n                      \n                    .","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"439_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jmg.2005.033522.","volume":"43","author":"K Janssens","year":"2006","unstructured":"Janssens K, Vanhoenacker F, Bonduelle M, Verbruggen L, Van Maldergem L, Ralston S, et al. Camurati-Engelmann disease: review of the clinical, radiological, and molecular data of 24 families and implications for diagnosis and treatment. J Med Genet. 2006;43(1):1\u201311. \n                      https:\/\/doi.org\/10.1136\/jmg.2005.033522.","journal-title":"J Med Genet"},{"issue":"10","key":"439_CR80","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1007\/s00198-016-3604-9","volume":"27","author":"M Carlo Di","year":"2016","unstructured":"Di Carlo M, Silveri F, Tardella M, Carotti M, Salaffi F. Multiple diaphyseal sclerosis (Ribbing disease): what about neridronate? Osteoporos Int. 2016;27(10):3127\u201331. \n                      https:\/\/doi.org\/10.1007\/s00198-016-3604-9\n                      \n                    .","journal-title":"Osteoporos Int"},{"issue":"3","key":"439_CR81","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/81563","volume":"26","author":"K Janssens","year":"2000","unstructured":"Janssens K, Gershoni-Baruch R, Guanabens N, Migone N, Ralston S, Bonduelle M, et al. Mutations in the gene encoding the latency-associated peptide of TGF-beta 1 cause Camurati-Engelmann disease. Nat Genet. 2000;26(3):273\u20135. \n                      https:\/\/doi.org\/10.1038\/81563\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"1","key":"439_CR82","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/79128.","volume":"26","author":"A Kinoshita","year":"2000","unstructured":"Kinoshita A, Saito T, Tomita H, Makita Y, Yoshida K, Ghadami M, et al. Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease. Nat Genet. 2000;26(1):19\u201320. \n                      https:\/\/doi.org\/10.1038\/79128.","journal-title":"Nat Genet"},{"issue":"7","key":"439_CR83","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nm.1979","volume":"15","author":"Y Tang","year":"2009","unstructured":"Tang Y, Wu X, Lei W, Pang L, Wan C, Shi Z, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009;15(7):757\u201365. \n                      https:\/\/doi.org\/10.1038\/nm.1979\n                      \n                    .","journal-title":"Nat Med"},{"issue":"5","key":"439_CR84","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1002\/jbmr.283","volume":"26","author":"MP Whyte","year":"2011","unstructured":"Whyte MP, Totty WG, Novack DV, Zhang X, Wenkert D, Mumm S. Camurati-Engelmann disease: unique variant featuring a novel mutation in TGFbeta1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand. J Bone Miner Res. 2011;26(5):920\u201333. \n                      https:\/\/doi.org\/10.1002\/jbmr.283\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"1","key":"439_CR85","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ajmg.10079","volume":"107","author":"G Nishimura","year":"2002","unstructured":"Nishimura G, Nishimura H, Tanaka Y, Makita Y, Ikegawa S, Ghadami M, et al. Camurati-Engelmann disease type II: progressive diaphyseal dysplasia with striations of the bones. Am J Med Genet. 2002;107(1):5\u201311.","journal-title":"Am J Med Genet"},{"issue":"3","key":"439_CR86","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2214\/ajr.167.3.8751682","volume":"167","author":"LL Seeger","year":"1996","unstructured":"Seeger LL, Hewel KC, Yao L, Gold RH, Mirra JM, Chandnani VP, et al. Ribbing disease (multiple diaphyseal sclerosis): imaging and differential diagnosis. AJR Am J Roentgenol. 1996;167(3):689\u201394. \n                      https:\/\/doi.org\/10.2214\/ajr.167.3.8751682\n                      \n                    .","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"439_CR87","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000322561.","volume":"194","author":"P Nieminen","year":"2011","unstructured":"Nieminen P, Lukinmaa PL, Alapulli H, Methuen M, Suojarvi T, Kivirikko S, et al. DLX3 homeodomain mutations cause tricho-dento-osseous syndrome with novel phenotypes. Cells Tissues Organs. 2011;194(1):49\u201359. \n                      https:\/\/doi.org\/10.1159\/000322561.","journal-title":"Cells Tissues Organs"},{"issue":"4","key":"439_CR88","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/eos.12197","volume":"123","author":"Y Li","year":"2015","unstructured":"Li Y, Han D, Zhang H, Liu H, Wong S, Zhao N, et al. Morphological analyses and a novel de novo DLX3 mutation associated with tricho-dento-osseous syndrome in a Chinese family. Eur J Oral Sci. 2015;123(4):228\u201334. \n                      https:\/\/doi.org\/10.1111\/eos.12197\n                      \n                    .","journal-title":"Eur J Oral Sci"},{"issue":"10","key":"439_CR89","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1136\/jmg.35.10.825","volume":"35","author":"JA Price","year":"1998","unstructured":"Price JA, Wright JT, Kula K, Bowden DW, Hart TC. A common DLX3 gene mutation is responsible for tricho-dento-osseous syndrome in Virginia and North Carolina families. J Med Genet. 1998;35(10):825\u20138.","journal-title":"J Med Genet"},{"issue":"3","key":"439_CR90","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/hmg\/7.3.563","volume":"7","author":"JA Price","year":"1998","unstructured":"Price JA, Bowden DW, Wright JT, Pettenati MJ, Hart TC. Identification of a mutation in DLX3 associated with tricho-dento-osseous (TDO) syndrome. Hum Mol Genet. 1998;7(3):563\u20139.","journal-title":"Hum Mol Genet"},{"key":"439_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/srep38680","volume":"6","author":"N Zhao","year":"2016","unstructured":"Zhao N, Han D, Liu H, Li Y, Wong SW, Cao Z, et al. Senescence: novel insight into DLX3 mutations leading to enhanced bone formation in tricho-dento-osseous syndrome. Sci Rep. 2016;6:38680. \n                      https:\/\/doi.org\/10.1038\/srep38680\n                      \n                    .","journal-title":"Sci Rep"},{"issue":"12","key":"439_CR92","first-page":"133","volume":"10","author":"WD Lenz","year":"1974","unstructured":"Lenz WD, Majewski F. A generalized disorders of the connective tissues with progeria, choanal atresia, symphalangism, hypoplasia of dentine and craniodiaphyseal hypostosis. Birth Defects Orig Artic Ser. 1974;10(12):133\u20136.","journal-title":"Birth Defects Orig Artic Ser"},{"issue":"4","key":"439_CR93","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/1096-8628(20000814)93:4<335::AID-AJMG14>3.0.CO;2-5","volume":"93","author":"F Majewski","year":"2000","unstructured":"Majewski F. Lenz-Majewski hyperostotic dwarfism: reexamination of the original patient. Am J Med Genet. 2000;93(4):335\u20138.","journal-title":"Am J Med Genet"},{"issue":"1","key":"439_CR94","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/ng.2829","volume":"46","author":"SB Sousa","year":"2014","unstructured":"Sousa SB, Jenkins D, Chanudet E, Tasseva G, Ishida M, Anderson G, et al. Gain-of-function mutations in the phosphatidylserine synthase 1 (PTDSS1) gene cause Lenz-Majewski syndrome. Nat Genet. 2014;46(1):70\u20136. \n                      https:\/\/doi.org\/10.1038\/ng.2829\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"3","key":"439_CR95","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/01.mcd.0000127468.11641.b7","volume":"13","author":"D Wattanasirichaigoon","year":"2004","unstructured":"Wattanasirichaigoon D, Visudtibhan A, Jaovisidha S, Laothamatas J, Chunharas A. Expanding the phenotypic spectrum of Lenz-Majewski syndrome: facial palsy, cleft palate and hydrocephalus. Clin Dysmorphol. 2004;13(3):137\u201342.","journal-title":"Clin Dysmorphol"},{"issue":"4","key":"439_CR96","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/jbmr.2398","volume":"30","author":"MP Whyte","year":"2015","unstructured":"Whyte MP, Blythe A, McAlister WH, Nenninger AR, Bijanki VN, Mumm S. Lenz-Majewski hyperostotic dwarfism with hyperphosphoserinuria from a novel mutation in PTDSS1 encoding phosphatidylserine synthase 1. J Bone Miner Res. 2015;30(4):606\u201314. \n                      https:\/\/doi.org\/10.1002\/jbmr.2398\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"3","key":"439_CR97","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.msec.2013.01.005","volume":"33","author":"C Xu","year":"2013","unstructured":"Xu C, Zheng Z, Fang L, Zhao N, Lin Z, Liang T, et al. Phosphatidylserine enhances osteogenic differentiation in human mesenchymal stem cells via ERK signal pathways. Mater Sci Eng C Mater Biol Appl. 2013;33(3):1783\u20138. \n                      https:\/\/doi.org\/10.1016\/j.msec.2013.01.005\n                      \n                    .","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"8","key":"439_CR98","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00296-010-1664-2","volume":"31","author":"AE Ozdemirel","year":"2011","unstructured":"Ozdemirel AE, Cakit BD, Erdem HR, Koc B. A rare benign disorder mimicking metastasis on radiographic examination: a case report of osteopoikilosis. Rheumatol Int. 2011;31(8):1113\u20136. \n                      https:\/\/doi.org\/10.1007\/s00296-010-1664-2\n                      \n                    .","journal-title":"Rheumatol Int"},{"issue":"3","key":"439_CR99","first-page":"177","volume":"6","author":"J Mahbouba","year":"2015","unstructured":"Mahbouba J, Mondher G, Amira M, Walid M, Naceur B. Osteopoikilosi: a rare cause of bone pain. Caspian J Intern Med. 2015;6(3):177\u20139.","journal-title":"Caspian J Intern Med"},{"issue":"11","key":"439_CR100","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/ng1453","volume":"36","author":"J Hellemans","year":"2004","unstructured":"Hellemans J, Preobrazhenska O, Willaert A, Debeer P, Verdonk PC, Costa T, et al. Loss-of-function mutations in LEMD3 result in osteopoikilosis, Buschke-Ollendorff syndrome and melorheostosis. Nat Genet. 2004;36(11):1213\u20138. \n                      https:\/\/doi.org\/10.1038\/ng1453\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"6","key":"439_CR101","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0190.","volume":"49","author":"T Ehrig","year":"2003","unstructured":"Ehrig T, Cockerell CJ. Buschke-Ollendorff syndrome: report of a case and interpretation of the clinical phenotype as a type 2 segmental manifestation of an autosomal dominant skin disease. J Am Acad Dermatol. 2003;49(6):1163\u20136. \n                      https:\/\/doi.org\/10.1016\/S0190.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"439_CR102","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1359\/jbmr.061102.","volume":"22","author":"S Mumm","year":"2007","unstructured":"Mumm S, Wenkert D, Zhang X, McAlister WH, Mier RJ, Whyte MP. Deactivating germline mutations in LEMD3 cause osteopoikilosis and Buschke-Ollendorff syndrome, but not sporadic melorheostosis. J Bone Miner Res. 2007;22(2):243\u201350. \n                      https:\/\/doi.org\/10.1359\/jbmr.061102.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"439_CR103","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s11914-017-0375-y","volume":"15","author":"A Kotwal","year":"2017","unstructured":"Kotwal A, Clarke BL. Melorheostosis: a rare sclerosing bone dysplasia. Curr Osteoporos Rep. 2017;15(4):335\u201342. \n                      https:\/\/doi.org\/10.1007\/s11914-017-0375-y\n                      \n                    .","journal-title":"Curr Osteoporos Rep"},{"issue":"3","key":"439_CR104","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1002\/humu.9403","volume":"27","author":"J Hellemans","year":"2006","unstructured":"Hellemans J, Debeer P, Wright M, Janecke A, Kjaer KW, Verdonk PC, et al. Germline LEMD3 mutations are rare in sporadic patients with isolated melorheostosis. Hum Mutat. 2006;27(3):290. \n                      https:\/\/doi.org\/10.1002\/humu.9403\n                      \n                    .","journal-title":"Hum Mutat"},{"key":"439_CR105","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bone.2017.04.010","volume":"101","author":"MP Whyte","year":"2017","unstructured":"Whyte MP, Griffith M, Trani L, Mumm S, Gottesman GS, McAlister WH, et al. Melorheostosis: exome sequencing of an associated dermatosis implicates postzygotic mosaicism of mutated KRAS. Bone. 2017;101:145\u201355. \n                      https:\/\/doi.org\/10.1016\/j.bone.2017.04.010\n                      \n                    .","journal-title":"Bone"},{"issue":"1","key":"439_CR106","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s12018-016-9226-0","volume":"15","author":"N Alonso","year":"2017","unstructured":"Alonso N, Calero-Paniagua I, Del Pino-Montes J. Clinical and genetic advances in Paget\u2019s disease of bone: a review. Clin Rev Bone Miner Metab. 2017;15(1):37\u201348. \n                      https:\/\/doi.org\/10.1007\/s12018-016-9226-0\n                      \n                    .","journal-title":"Clin Rev Bone Miner Metab"},{"issue":"22","key":"439_CR107","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1093\/hmg\/11.22.2735","volume":"11","author":"LJ Hocking","year":"2002","unstructured":"Hocking LJ, Lucas GJ, Daroszewska A, Mangion J, Olavesen M, Cundy T, et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget\u2019s disease. Hum Mol Genet. 2002;11(22):2735\u20139.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"439_CR108","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1086\/340731","volume":"70","author":"N Laurin","year":"2002","unstructured":"Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1\/p62) in Paget disease of bone. Am J Hum Genet. 2002;70(6):1582\u20138. \n                      https:\/\/doi.org\/10.1086\/340731\n                      \n                    .","journal-title":"Am J Hum Genet"},{"issue":"6","key":"439_CR109","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/ng.562","volume":"42","author":"OM Albagha","year":"2010","unstructured":"Albagha OM, Visconti MR, Alonso N, Langston AL, Cundy T, Dargie R, et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget\u2019s disease of bone. Nat Genet. 2010;42(6):520\u20134. \n                      https:\/\/doi.org\/10.1038\/ng.562\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"7","key":"439_CR110","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ng.845","volume":"43","author":"OM Albagha","year":"2011","unstructured":"Albagha OM, Wani SE, Visconti MR, Alonso N, Goodman K, Brandi ML, et al. Genome-wide association identifies three new susceptibility loci for Paget\u2019s disease of bone. Nat Genet. 2011;43(7):685\u20139. \n                      https:\/\/doi.org\/10.1038\/ng.845\n                      \n                    .","journal-title":"Nat Genet"},{"issue":"2","key":"439_CR111","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/jbmr.542","volume":"27","author":"F Gianfrancesco","year":"2012","unstructured":"Gianfrancesco F, Rendina D, Di Stefano M, Mingione A, Esposito T, Merlotti D, et al. A nonsynonymous TNFRSF11A variation increases NFkappaB activity and the severity of Paget\u2019s disease. J Bone Miner Res. 2012;27(2):443\u201352. \n                      https:\/\/doi.org\/10.1002\/jbmr.542\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"11","key":"439_CR112","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/hmg\/ddv068","volume":"24","author":"M Vallet","year":"2015","unstructured":"\u2022 Vallet M, Soares DC, Wani S, Sophocleous A, Warner J, Salter DM, et al. Targeted sequencing of the Paget\u2019s disease associated 14q32 locus identifies several missense coding variants in RIN3 that predispose to Paget\u2019s disease of bone. Hum Mol Genet. 2015;24(11):3286\u201395. \n                      https:\/\/doi.org\/10.1093\/hmg\/ddv068\n                      \n                    . The sequencing effort reported in this study was the first to look into the genetic variation in the RIN3 gene in the context of human disease. This gene has been implicated in bone research following GWAS on Paget\u2019s disease and bone and BMD.","journal-title":"Hum Mol Genet"},{"issue":"6","key":"439_CR113","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.celrep.2015.09.071","volume":"13","author":"R Obaid","year":"2015","unstructured":"Obaid R, Wani SE, Azfer A, Hurd T, Jones R, Cohen P, et al. Optineurin negatively regulates osteoclast differentiation by modulating NF-kappaB and interferon signaling: implications for Paget\u2019s disease. Cell Rep. 2015;13(6):1096\u2013102. \n                      https:\/\/doi.org\/10.1016\/j.celrep.2015.09.071\n                      \n                    .","journal-title":"Cell Rep"},{"issue":"1","key":"439_CR114","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12881-017-0495-3","volume":"18","author":"E Laurier","year":"2017","unstructured":"Laurier E, Amiable N, Gagnon E, Brown JP, Michou L. Effect of a rare genetic variant of TM7SF4 gene on osteoclasts of patients with Paget\u2019s disease of bone. BMC Med Genet. 2017;18(1):133. \n                      https:\/\/doi.org\/10.1186\/s12881-017-0495-3\n                      \n                    .","journal-title":"BMC Med Genet"},{"key":"439_CR115","doi-asserted-by":"crossref","unstructured":"Watts GDJ, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36:377\u201381. https:\/\/doi.org\/10.1038\/ng1332 https:\/\/www.nature.com\/articles\/ng1332#supplementary-information.","DOI":"10.1038\/ng1332"},{"issue":"7442","key":"439_CR116","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature11922","volume":"495","author":"HJ Kim","year":"2013","unstructured":"Kim HJ, Kim NC, Wang YD, Scarborough EA, Moore J, Diaz Z, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495(7442):467\u201373. \n                      https:\/\/doi.org\/10.1038\/nature11922\n                      \n                    .","journal-title":"Nature"},{"issue":"2","key":"439_CR117","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00223-017-0269-0","volume":"101","author":"X Qi","year":"2017","unstructured":"Qi X, Pang Q, Wang J, Zhao Z, Wang O, Xu L, et al. Familial early-onset Paget\u2019s disease of bone associated with a novel hnRNPA2B1 mutation. Calcif Tissue Int. 2017;101(2):159\u201369. \n                      https:\/\/doi.org\/10.1007\/s00223-017-0269-0\n                      \n                    .","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"439_CR118","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ymgme.2011.03.021","volume":"103","author":"PY Chung","year":"2011","unstructured":"Chung PY, Beyens G, de Freitas F, Boonen S, Geusens P, Vanhoenacker F, et al. Indications for a genetic association of a VCP polymorphism with the pathogenesis of sporadic Paget\u2019s disease of bone, but not for TNFSF11 (RANKL) and IL-6 polymorphisms. Mol Genet Metab. 2011;103(3):287\u201392. \n                      https:\/\/doi.org\/10.1016\/j.ymgme.2011.03.021\n                      \n                    .","journal-title":"Mol Genet Metab"},{"issue":"6","key":"439_CR119","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1089\/gtmb.2015.0292","volume":"20","author":"R Usategui-Martin","year":"2016","unstructured":"Usategui-Martin R, Calero-Paniagua I, Garcia-Aparicio J, Corral-Gudino L, Del Pino Montes J, Gonzalez Sarmiento R. VAV3 gene polymorphism is associated with Paget\u2019s disease of bone. Genet Test Mol Biomarkers. 2016;20(6):335\u20137. \n                      https:\/\/doi.org\/10.1089\/gtmb.2015.0292\n                      \n                    .","journal-title":"Genet Test Mol Biomarkers"},{"issue":"3","key":"439_CR120","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nm1194","volume":"11","author":"R Faccio","year":"2005","unstructured":"Faccio R, Teitelbaum SL, Fujikawa K, Chappel J, Zallone A, Tybulewicz VL, et al. Vav3 regulates osteoclast function and bone mass. Nat Med. 2005;11(3):284\u201390. \n                      https:\/\/doi.org\/10.1038\/nm1194\n                      \n                    .","journal-title":"Nat Med"},{"issue":"6","key":"439_CR121","doi-asserted-by":"publisher","first-page":"e0128984","DOI":"10.1371\/journal.pone.0128984","volume":"10","author":"R Usategui-Martin","year":"2015","unstructured":"Usategui-Martin R, Garcia-Aparicio J, Corral-Gudino L, Calero-Paniagua I, Del Pino-Montes J, Gonzalez Sarmiento R. Polymorphisms in autophagy genes are associated with Paget disease of bone. PLoS One. 2015;10(6):e0128984. \n                      https:\/\/doi.org\/10.1371\/journal.pone.0128984\n                      \n                    .","journal-title":"PLoS One"},{"issue":"7219","key":"439_CR122","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nature07383","volume":"456","author":"T Saitoh","year":"2008","unstructured":"Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature. 2008;456(7219):264\u20138. \n                      https:\/\/doi.org\/10.1038\/nature07383\n                      \n                    .","journal-title":"Nature"},{"issue":"7020","key":"439_CR123","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/nature03029","volume":"432","author":"A Kuma","year":"2004","unstructured":"Kuma A, Hatano M, Matsui M, Yamamoto A, Nakaya H, Yoshimori T, et al. The role of autophagy during the early neonatal starvation period. Nature. 2004;432(7020):1032\u20136. \n                      https:\/\/doi.org\/10.1038\/nature03029\n                      \n                    .","journal-title":"Nature"},{"issue":"5","key":"439_CR124","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1038\/emm.2017.64","volume":"49","author":"B Lu","year":"2017","unstructured":"\u2022 Lu B, Jiao Y, Wang Y, Dong J, Wei M, Cui B, et al. A FKBP5 mutation is associated with Paget\u2019s disease of bone and enhances osteoclastogenesis. Exp Mol Med. 2017;49(5):e336. \n                      https:\/\/doi.org\/10.1038\/emm.2017.64\n                      \n                    . Using WES, the authors identified mutations in a previously unreported gene for Paget\u2019s disease of bone and deliver functional evidence for its potential involvement.","journal-title":"Exp Mol Med"},{"issue":"2","key":"439_CR125","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ajhg.2015.12.016","volume":"98","author":"G Divisato","year":"2016","unstructured":"Divisato G, Formicola D, Esposito T, Merlotti D, Pazzaglia L, Del Fattore A, et al. ZNF687 mutations in severe Paget disease of bone associated with giant cell tumor. Am J Hum Genet. 2016;98(2):275\u201386. \n                      https:\/\/doi.org\/10.1016\/j.ajhg.2015.12.016\n                      \n                    .","journal-title":"Am J Hum Genet"},{"key":"439_CR126","doi-asserted-by":"publisher","unstructured":"Divisato G, di Carlo FS, Petrillo N, Esposito T, Gianfrancesco F. ZNF687 mutations are frequently found in pagetic patients from South Italy: implication in the pathogenesis of Paget\u2019s disease of bone. Clin Genet. 2018; \n                      https:\/\/doi.org\/10.1111\/cge.13247\n                      \n                    .","DOI":"10.1111\/cge.13247"},{"issue":"38","key":"439_CR127","doi-asserted-by":"publisher","first-page":"63121","DOI":"10.18632\/oncotarget.18670.","volume":"8","author":"G Divisato","year":"2017","unstructured":"Divisato G, Scotto di Carlo F, Pazzaglia L, Rizzo R, Coviello DA, Benassi MS, et al. The distinct clinical features of giant cell tumor of bone in pagetic and non-pagetic patients are associated with genetic, biochemical and histological differences. Oncotarget. 2017;8(38):63121\u201331. \n                      https:\/\/doi.org\/10.18632\/oncotarget.18670.","journal-title":"Oncotarget"},{"issue":"8","key":"439_CR128","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1084\/jem.20150407","volume":"212","author":"MB Greenblatt","year":"2015","unstructured":"Greenblatt MB, Park KH, Oh H, Kim JM, Shin DY, Lee JM, et al. CHMP5 controls bone turnover rates by dampening NF-kappaB activity in osteoclasts. J Exp Med. 2015;212(8):1283\u2013301. \n                      https:\/\/doi.org\/10.1084\/jem.20150407\n                      \n                    .","journal-title":"J Exp Med"},{"issue":"4","key":"439_CR129","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.bone.2012.06.028","volume":"51","author":"L Michou","year":"2012","unstructured":"Michou L, Conceicao N, Morissette J, Gagnon E, Miltenberger-Miltenyi G, Siris ES, et al. Genetic association study of UCMA\/GRP and OPTN genes (PDB6 locus) with Paget\u2019s disease of bone. Bone. 2012;51(4):720\u20138. \n                      https:\/\/doi.org\/10.1016\/j.bone.2012.06.028\n                      \n                    .","journal-title":"Bone"},{"issue":"7","key":"439_CR130","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1359\/jbmr.070333","volume":"22","author":"G Beyens","year":"2007","unstructured":"Beyens G, Daroszewska A, de Freitas F, Fransen E, Vanhoenacker F, Verbruggen L, et al. Identification of sex-specific associations between polymorphisms of the osteoprotegerin gene, TNFRSF11B, and Paget\u2019s disease of bone. J Bone Miner Res. 2007;22(7):1062\u201371. \n                      https:\/\/doi.org\/10.1359\/jbmr.070333\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"18","key":"439_CR131","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/hmg\/11.18.2119","volume":"11","author":"T Cundy","year":"2002","unstructured":"Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet. 2002;11(18):2119\u201327.","journal-title":"Hum Mol Genet"},{"issue":"8","key":"439_CR132","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1359\/jbmr.2003.18.8.1381","volume":"18","author":"K Nakatsuka","year":"2003","unstructured":"Nakatsuka K, Nishizawa Y, Ralston SH. Phenotypic characterization of early onset Paget\u2019s disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res. 2003;18(8):1381\u20135. \n                      https:\/\/doi.org\/10.1359\/jbmr.2003.18.8.1381\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"1","key":"439_CR133","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1359\/jbmr.2002.17.1.26","volume":"17","author":"MP Whyte","year":"2002","unstructured":"Whyte MP, Hughes AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res. 2002;17(1):26\u20139. \n                      https:\/\/doi.org\/10.1359\/jbmr.2002.17.1.26\n                      \n                    .","journal-title":"J Bone Miner Res"},{"issue":"1","key":"439_CR134","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/71667","volume":"24","author":"AE Hughes","year":"2000","unstructured":"Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24(1):45\u20138. \n                      https:\/\/doi.org\/10.1038\/71667\n                      \n                    .","journal-title":"Nat Genet"},{"key":"439_CR135","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bone.2014.07.019","volume":"68","author":"MP Whyte","year":"2014","unstructured":"Whyte MP, Tau C, McAlister WH, Zhang X, Novack DV, Preliasco V, et al. Juvenile Paget\u2019s disease with heterozygous duplication within TNFRSF11A encoding RANK. Bone. 2014;68:153\u201361. \n                      https:\/\/doi.org\/10.1016\/j.bone.2014.07.019\n                      \n                    .","journal-title":"Bone"},{"issue":"2","key":"439_CR136","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3325\/cmj.2015.56.145","volume":"56","author":"J Donath","year":"2015","unstructured":"Donath J, Speer G, Kosa JP, Arvai K, Balla B, Juhasz P, et al. Polymorphisms of CSF1 and TM7SF4 genes in a case of mild juvenile Paget\u2019s disease found using next-generation sequencing. Croat Med J. 2015;56(2):145\u201351.","journal-title":"Croat Med J"},{"issue":"1","key":"439_CR137","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1358\/dnp.2004.17.1.829022","volume":"17","author":"BR Troen","year":"2004","unstructured":"Troen BR. The role of cathepsin K in normal bone resorption. Drug News Perspect. 2004;17(1):19\u201328.","journal-title":"Drug News Perspect"},{"issue":"5","key":"439_CR138","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1517\/13543780902832661","volume":"18","author":"D Bromme","year":"2009","unstructured":"Bromme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs. 2009;18(5):585\u2013600. \n                      https:\/\/doi.org\/10.1517\/13543780902832661\n                      \n                    .","journal-title":"Expert Opin Investig Drugs"},{"issue":"15","key":"439_CR139","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"\u2022 Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417\u201327. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1708322\n                      \n                    . The authors demonstrate that preceeding alendronate treatment with romosozumab administration decreases the risk of fracture more significantly than that of alendronate treatment alone in postmenopausal patients with high risk of fracture.","journal-title":"N Engl J Med"},{"issue":"10","key":"439_CR140","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1759720X17726744","volume":"9","author":"MR McClung","year":"2017","unstructured":"McClung MR. Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential. Ther Adv Musculoskelet Dis. 2017;9(10):263\u201370. \n                      https:\/\/doi.org\/10.1177\/1759720X17726744\n                      \n                    .","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-018-0439-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-018-0439-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-018-0439-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T19:45:39Z","timestamp":1555184739000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-018-0439-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,14]]},"references-count":140,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["439"],"URL":"https:\/\/doi.org\/10.1007\/s11914-018-0439-7","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,14]]},"assertion":[{"value":"14 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Rapha\u00ebl De Ridder, Eveline Boudin, Geert Mortier, and Wim Van Hul declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}